Skip to content
GLP-1 Calculators

Stopping GLP-1 Weight Regain in 2026 — STEP 4 and SURMOUNT-4 Projection

Expected regain over 72 weeks after stopping semaglutide or tirzepatide — grounded in STEP 4 and SURMOUNT-4 withdrawal RCTs.

Updated April 2026

Medical disclaimer: This tool is for informational purposes. Not medical advice. Consult your healthcare provider before starting, stopping, or changing any medication. Drug prices, savings cards, and coverage policies change frequently — verify current pricing directly with the manufacturer or your pharmacy.

Your inputs

Results

Expected regain at 1 year
28 lb
asymptote: 30 lb of 45 lost
Weight at 1 year
203 lb
Regain %
66%
of original loss
STEP 4 randomized patients at week 20 to continue semaglutide 2.4 mg or switch to placebo. Continuers lost another 8%; placebo switchers regained two-thirds of initial loss within 48 weeks. GLP-1 obesity pharmacotherapy is chronic-disease treatment, not a course.
Post-stop weight trajectory (week 0 = day you stop)

The data you need before you stop

Two randomized withdrawal trials define what happens after you discontinue GLP-1 weight-loss pharmacotherapy.

STEP 4 (Rubino et al., JAMA 2021): 803 adults completed 20 weeks of semaglutide 2.4 mg run-in, losing ~10.6% body weight. Randomized 2:1 to continue or placebo for 48 more weeks. Continuers: additional 7.9% loss, total ~17.4%. Placebo switchers: regained 6.9%, total reduction ~5.0%. Over 48 weeks, switchers regained roughly two-thirds of what they had lost.

SURMOUNT-4 (Aronne et al., 2024): 670 adults completed 36 weeks of tirzepatide up to 15 mg, losing ~20.9%. Randomized to continue or placebo for 52 weeks. Continuers: additional 5.5%, total ~25.3%. Placebo switchers: regained 14%, total ~9.9%. Bigger original loss, bigger absolute regain.

Why the weight comes back

  1. Appetite rebounds immediately. GLP-1 receptor agonism stops within 2–4 weeks. Ghrelin rises; PYY/GLP-1 endogenous signaling normalizes. Hunger returns to pre-treatment level within 4–6 weeks.
  2. Set-point biology pulls hard. Rosenbaum/Leibel metabolic adaptation data: RMR drops 8–15% below predicted at new lower weight and persists for years.
  3. Behavioral bandwidth returns to baseline. Patients who lost on GLP-1 without building food/activity habits have no scaffolding when appetite returns.

Four stopping strategies

1. Cold turkey.The STEP 4 / SURMOUNT-4 scenario. Expect 60–70% regain over 12–18 months without behavioral intervention; 40–55% with aggressive protein + resistance + tracking.

2. Taper over 3–6 months.Semaglutide 2.4 → 1.7 → 1.0 → 0.5 → off. No RCT data, but physiologically gives set-point system time to adapt. Anecdotal reports ~30–50% regain over 12 months.

3. Maintenance dose.Lowest dose that prevents regain. Semaglutide 0.5–1.0 mg; tirzepatide 5–7.5 mg. Expected regain: 10–25% over a year.

4. Bridge to bariatric surgery or next-gen therapy.Sleeve/bypass produces durable 25–30% loss. Future therapies (orforglipron, retatrutide, cagrilintide-sema combos) may produce better outcomes.

When stopping is the right decision

  • Pregnancy or planning within 2 months: mandatory discontinuation.
  • Intolerable GI side effects despite dose reduction, antiemetics, dietary mod after 2–3 months of troubleshooting.
  • Cost prohibitive with no alternative path: stopping beats skipping doses or stretching pens.
  • Acute pancreatitis, gallstones requiring surgery, MTC diagnosis: clinical contraindications.
  • Goal achieved with aggressive maintenance plan: hardest case, individual discussion with prescriber.

Practical stopping protocol

  1. Weeks 1–4 post-stop: keep food logging. Weight weekly, not daily. Expect 2–4 lb water regain — not fat.
  2. Weeks 4–12: appetite bounces hardest. Pre-plan meals. Protein 0.8–1.0 g/lb. 3+ resistance sessions/week non-negotiable.
  3. Months 3–6: regain curve steepens. Gaining > 1 lb/week: call prescriber. Restart low-dose is an option.
  4. Months 6–12: regain decelerates. Below 30% regain = working. Above 50% = consider resuming.
Related tools
Maintenance dose cost
Indefinite therapy budget.
Weight loss timeline
Expected loss by week.
Muscle loss risk
Preservation during loss phase.
BMI trajectory
52-week BMI plot by therapy.
Cost per pound lost
Full cost-effectiveness math.
Wegovy vs Zepbound
If considering a switch instead.

Frequently asked questions

If I resume GLP-1 after stopping, will I lose the weight again?

Yes. Limited data on restart show similar response to original treatment. A 2024 analysis of stop-and-restart patients showed 85–90% recovered their previous nadir within 6 months of restarting. The drug still works; the set-point biology didn't change.

Can I take a 2–3 month drug holiday?

Physiologically possible. You'll regain some weight during the holiday and lose it again on restart. Why you'd do this is the real question — side effect break, cost gap, or life event. Discuss with prescriber; there's no trial evidence drug holidays are helpful, and regain during the gap is predictable.

Does stopping affect the SELECT cardiovascular benefit?

Yes. The 20% MACE reduction in SELECT required continued semaglutide through 39.8 months median follow-up. Stopping almost certainly reverses the benefit over time, though durability post-stop isn't formally studied. If you're on Wegovy for the CV indication specifically, the stop decision should involve cardiology.

How much regain should I actually expect?

STEP 4 (semaglutide withdrawal): patients regained 6.9% over 48 weeks — roughly two-thirds of what they'd lost. SURMOUNT-4 (tirzepatide): regained 14% over 52 weeks after stopping, also roughly two-thirds. Regain is sharpest months 2–6 post-stop, tapering toward week 48. Bigger original losses come with bigger absolute regain.

Are there non-GLP-1 drugs that help prevent regain?

Phentermine-topiramate (Qsymia) and bupropion-naltrexone (Contrave) have limited but non-zero evidence as post-GLP-1 maintenance. Metformin may help patients with insulin resistance. None match the mechanism of a GLP-1 RA. If maintenance is your goal, a low-dose GLP-1 is usually the better answer.

What's the maintenance dose strategy?

Instead of stopping, reduce to the lowest dose that prevents regain. Semaglutide 0.5–1.0 mg weekly, or tirzepatide 5–7.5 mg, after goal weight, often balances cost, side effects, and regain prevention. Expected regain on maintenance: 10–25% over a year — vs 60–70% cold turkey.

Who does better on discontinuation?

Patients who lost < 10% total body weight on therapy, patients who added structured resistance training (3+ sessions/week), patients who maintained 0.8–1.0 g/lb protein through therapy, younger patients (set-point plasticity), and patients without T2D. Older patients with T2D who lost > 15% body weight have the highest regain risk.

What does the chronic-disease framing mean for me?

The Obesity Medicine Association and Endocrine Society position: GLP-1 is chronic pharmacotherapy for a chronic disease. Stopping antihypertensives raises BP; stopping statins raises LDL; stopping GLP-1 raises weight. Expecting sustained loss after stopping is biologically unrealistic for most patients. This reframing changes the cost-effectiveness math.

Digital Dashboard Hub

Track your GLP-1 progress, weight loss, and health metrics

DDH has 54 health and wellness trackers — weight loss logs, BMI history, symptom tracking, and habit tools — built for your GLP-1 journey. Free 14-day trial.

Track your GLP-1 journey free →
Part of the Digital Dashboard Hub network
Powered byDigital Dashboard Hub— 250+ free tools

Calculators, trackers, and planners for creators, business, and wellness — all in one place.

Explore all 250+ tools →